RSPO1 Protein (Native, Human)

1.Measured by its ability to induce activation of ßcatenin response in a Topflash Luciferase assay using HEK293T human embryonic kidney cells. The ED50 for this effect is typically 10-80 ng/mL in the presence of 5 ng/mL recombinant mouse Wnt3a. 2.Human intestinal cancer organoids were cultured with RSPO1 (Cat#11083-HNAS), EGF (Cat#50482-MNCH), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology. 3.Human colorectum organoids were cultured with RSPO1 (Cat#11083-HNAS), EGF (Cat#50482-MNCH), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology. 4.Human lung cancer organoids were cultured with FGF2 (Cat#10014-HNAE), FGF4 (Cat#16043-HNAE), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 5.Human lung organoids were cultured with FGF2 (Cat#10014-HNAE), FGF4 (Cat#16043-HNAE), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 6.Human cholangiocarcinomas organoids were cultured with FGF2 (Cat#10014-HNAE), HGF (Cat#10463-HNAS), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 7.Human liver cancer organoids were cultured with FGF2 (Cat#10014-HNAE), HGF (Cat#10463-HNAS), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), TGFB1 (Cat#10804-HNAC), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 8.Human kidney cancer organoids were cultured with FGF2 (Cat#10014-HNAE), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 9.Human kidney organoids were cultured with FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS), HGF (Cat#10463-HNAS), FGF4 (Cat#16043-HNAE) . (Routinely tested) . Data provided by D1 Medical Technology. 10.Human gastric cancer organoids were cultured with EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 11.Human stomach organoids organoids were cultured with EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 12.Human breast cancer organoids were cultured with FGF7 (Cat#10210-H07E), RSPO1 (Cat#11083-HNAS), IGF1 (Cat#10598-HNAE), EGF (Cat#50482-MNCH), NRG1 Beta 1 (Cat#11609-H01H), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology. 13.Human ovarian organoids were cultured with IGF1 (Cat#10598-HNAE), NRG1 Beta 1 (Cat#11609-H01H), RSPO1 (Cat#11083-HNAS), EGF (Cat#50482-MNCH), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology.

The recombinant human RSPO1 consists of 243 amino acids and has a predicted molecular mass of 26.8 kDa. As a result of glycosylation, the apparent molecular mass of it is approximately 40 and 31 kDa in SDS-PAGE under reducing conditions.